Boston Scientific Corporation (ETR:BSX)

Revance Therapeutics Statistics

Total Valuation

ETR:BSX has a market cap or net worth of EUR 131.17 billion. The enterprise value is 141.26 billion.

Market Cap	131.17B
Enterprise Value	141.26B

Important Dates

The last earnings date was Wednesday, July 23, 2025.

Earnings Date	Jul 23, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	1.48B
Shares Outstanding	n/a
Shares Change (YoY)	+0.78%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.48B

Valuation Ratios

The trailing PE ratio is 61.50 and the forward PE ratio is 32.83.

PE Ratio	61.50
Forward PE	32.83
PS Ratio	8.33
PB Ratio	6.80
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 34.20, with an EV/FCF ratio of 47.60.

EV / Earnings	66.22
EV / Sales	8.88
EV / EBITDA	34.20
EV / EBIT	48.46
EV / FCF	47.60

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.53.

Current Ratio	1.37
Quick Ratio	0.65
Debt / Equity	0.53
Debt / EBITDA	2.50
Debt / FCF	3.45
Interest Coverage	10.24

Financial Efficiency

Return on equity (ROE) is 11.55% and return on invested capital (ROIC) is 6.40%.

Return on Equity (ROE)	11.55%
Return on Assets (ROA)	5.39%
Return on Invested Capital (ROIC)	6.40%
Return on Capital Employed (ROCE)	9.32%
Revenue Per Employee	297,125
Profits Per Employee	40,245
Employee Count	53,000
Asset Turnover	0.47
Inventory Turnover	2.16

Taxes

In the past 12 months, ETR:BSX has paid 427.45 million in taxes.

Income Tax	427.45M
Effective Tax Rate	16.73%

Stock Price Statistics

The stock price has increased by +30.37% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+30.37%
50-Day Moving Average	89.13
200-Day Moving Average	89.84
Relative Strength Index (RSI)	42.84
Average Volume (20 Days)	153

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.63

Income Statement

In the last 12 months, ETR:BSX had revenue of EUR 15.75 billion and earned 2.13 billion in profits. Earnings per share was 1.43.

Revenue	15.75B
Gross Profit	10.72B
Operating Income	2.89B
Pretax Income	2.55B
Net Income	2.13B
EBITDA	4.01B
EBIT	2.89B
Earnings Per Share (EPS)	1.43

Balance Sheet

The company has 454.70 million in cash and 10.24 billion in debt, giving a net cash position of -9.79 billion.

Cash & Cash Equivalents	454.70M
Total Debt	10.24B
Net Cash	-9.79B
Net Cash Per Share	n/a
Equity (Book Value)	19.29B
Book Value Per Share	12.89
Working Capital	1.64B

Cash Flow

In the last 12 months, operating cash flow was 3.65 billion and capital expenditures -681.20 million, giving a free cash flow of 2.97 billion.

Operating Cash Flow	3.65B
Capital Expenditures	-681.20M
Free Cash Flow	2.97B
FCF Per Share	n/a

Margins

Gross margin is 68.04%, with operating and profit margins of 18.33% and 13.55%.

Gross Margin	68.04%
Operating Margin	18.33%
Pretax Margin	16.22%
Profit Margin	13.55%
EBITDA Margin	25.44%
EBIT Margin	18.33%
FCF Margin	18.84%

Dividends & Yields

ETR:BSX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.78%
Shareholder Yield	n/a
Earnings Yield	1.63%
FCF Yield	2.26%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on November 6, 2003. It was a forward split with a ratio of 2.

Last Split Date	Nov 6, 2003
Split Type	Forward
Split Ratio	2

Scores

ETR:BSX has an Altman Z-Score of 5.22 and a Piotroski F-Score of 5.

Altman Z-Score	5.22
Piotroski F-Score	5